CymaBay Therapeutics
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | 31.1m | 6.7m | - | 306m |
| % growth | - | - | - | - | (79 %) | - | - |
| EBITDA | (53.4m) | (86.7m) | (91.1m) | (85.7m) | (181m) | (108m) | - |
| % EBITDA margin | - | - | - | (276 %) | (2723 %) | - | - |
| Profit | (51.0m) | (90.0m) | (106m) | (105m) | (175m) | (158m) | (50.9m) |
| % profit margin | - | - | - | (339 %) | (2633 %) | - | (17 %) |
| EV / revenue | - | - | - | 86.2x | 522.4x | - | 11.1x |
| EV / EBITDA | -7.4x | -1.7x | -5.3x | -31.2x | -19.2x | -32.3x | - |
| R&D budget | 35.9m | 64.5m | 68.0m | 80.8m | - | - | - |
| R&D % of revenue | - | - | - | 260 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $10.0m | Early VC | |
| N/A | $27.0m | Late VC | |
| N/A | N/A | - | |
$44.0m | Series B | ||
| N/A | $10.0m | Series C | |
$32.0m | Series D | ||
$27.7m | Debt | ||
| N/A | $8.6m | Early VC | |
$5.0m | Debt | ||
| N/A | N/A | IPO | |
$325k | Post IPO Debt | ||
* | N/A | $144m | Post IPO Equity |
$100m | Post IPO Debt | ||
* | N/A | $85.0m | Post IPO Equity |
* | N/A | $150m | Post IPO Equity |
* | N/A Valuation: $4.3b 138.4x EV/LTM Revenues -50.1x EV/LTM EBITDA | Acquisition | |
| Total Funding | CAD179m | ||
Related Content
Recent News about CymaBay Therapeutics
EditCymaBay Therapeutics is a biopharmaceutical company focused on developing innovative therapies to improve the lives of patients suffering from liver and other chronic diseases. The company operates primarily in the healthcare and pharmaceutical markets, targeting conditions such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).
CymaBay's flagship product is seladelpar, a drug designed to treat PBC, a chronic liver disease. The company is also exploring the potential of seladelpar in combination with other drugs like liraglutide and selonsertib to treat fibrosis and NASH, a liver condition caused by fat buildup. These efforts are supported by extensive clinical trials and research, including collaborations with various medical professionals and institutions.
The primary clients of CymaBay are patients with liver diseases, healthcare providers, and medical institutions. The company aims to provide these clients with access to cutting-edge treatments that can significantly improve patient outcomes and quality of life.
CymaBay's business model revolves around the research, development, and commercialization of its pharmaceutical products. The company invests heavily in clinical trials to ensure the safety and efficacy of its drugs. Once a drug is approved by regulatory authorities, CymaBay generates revenue through sales to healthcare providers and institutions. Additionally, the company may enter into licensing agreements or partnerships with other pharmaceutical companies to expand the reach of its therapies.
In summary, CymaBay Therapeutics is dedicated to advancing medical treatments for liver and chronic diseases through innovative drug development. The company serves patients, healthcare providers, and medical institutions, operating within the healthcare and pharmaceutical markets. Its business model focuses on research, clinical trials, and commercialization to generate revenue.
Keywords: biopharmaceutical, liver diseases, chronic diseases, seladelpar, primary biliary cholangitis, NASH, clinical trials, healthcare providers, drug development, innovative therapies.